Neogen Sells Genomics Arm to Zoetis in $160M Strategic Reset

LANSING, MI – March 02, 2026 – Neogen Corporation has announced a definitive agreement to sell its global genomics business to animal health giant Zoetis Inc. for $160 million. The move marks a significant strategic pivot for Neogen, allowing the food safety leader to sharpen its focus on core operations and aggressively tackle its substantial debt load. For Zoetis, the acquisition represents a major expansion of its diagnostic capabilities, further cementing its leadership position in the global animal health market.

The all-cash transaction, which is subject to regulatory approval and customary closing conditions, is expected to be finalized by the first half of Neogen’s 2027 fiscal year. The genomics business, which operates under the well-regarded GeneSeek® brand, generated approximately $90 million in sales during fiscal year 2025.

Neogen's Strategic Pivot: Debt Reduction and Renewed Focus

The divestiture is the latest and most significant step in Neogen's strategic portfolio review, a comprehensive effort to streamline the company and improve financial stability. Following a period of complex integration efforts and challenging market conditions, the sale provides a crucial infusion of capital aimed squarely at de-leveraging the company's balance sheet.

Neogen has been operating under considerable financial pressure, with total outstanding debt reported at $800 million as of August 2025. Rating agencies had taken note, with S&P Global Ratings citing an elevated adjusted leverage of 6.6x when it downgraded Neogen's credit rating in late 2025. The $160 million in proceeds from the genomics sale, which will be used primarily for debt reduction, is a critical component of the company's plan to restore its financial health. Analysts anticipate this move, combined with other recent divestitures, will help lower the company's leverage to a more manageable level, potentially around 4.4x by 2027.

“This transaction is part of the company’s strategic portfolio review and allows the company to accelerate de-leveraging and improve profitability going forward,” said Mike Nassif, Neogen’s Chief Executive Officer and President, in the official announcement. “Furthermore, this deal allows us to focus in areas where the company has the most significant competitive advantage and further leverage our core capabilities in food and animal safety.”

Profitability has been a key concern, with the company posting a significant net loss in fiscal year 2025, weighed down by over $50 million in costs related to the integration of 3M's food safety business. While the genomics business has been a pioneer in its field, selling the unit is expected to be margin-accretive for Neogen, allowing it to concentrate resources on its most profitable and synergistic divisions. The company will now double down on its core Food Safety and Animal Safety segments, focusing on high-growth areas like pathogen detection, hygiene monitoring, biosecurity products, and veterinary instruments.

Zoetis Deepens its Diagnostic Arsenal

While Neogen streamlines, Zoetis is expanding. As the world’s leading animal health company with a legacy spanning nearly 75 years, Zoetis is acquiring a business that will significantly bolster its portfolio in one of the industry's fastest-growing sectors: diagnostics and predictive health.

The acquisition of Neogen’s genomics business, a pioneer in advanced DNA testing for livestock and companion animals, provides Zoetis with powerful tools and a wealth of expertise. The GeneSeek business, with its flagship Igenity® and GGP® portfolios, offers returns-focused genomic tools that help accelerate herd improvement and screen for genetic traits in the beef and dairy industries.

This move aligns perfectly with Zoetis's long-term strategy of advancing animal care through science and data-driven innovation. By integrating GeneSeek’s capabilities, Zoetis can offer a more comprehensive suite of solutions that span the full continuum of care—from predicting genetic potential and disease risk to diagnosing and treating illness. This creates powerful synergies, allowing Zoetis to link genomic insights directly to its vast portfolio of vaccines, medicines, and other animal health products.

For veterinarians and livestock producers, this integration could mean a more holistic approach to animal management. The ability to use genetic data to make more informed breeding decisions, anticipate health challenges, and optimize treatment protocols represents the future of precision animal agriculture and personalized pet care, a future Zoetis is now better positioned to lead.

A Reshaped Competitive Landscape

The transaction is set to send ripples across the animal health industry, fundamentally altering the competitive landscape for animal genomics. The consolidation of a leading independent genomics provider under the umbrella of the industry's largest player creates a formidable force.

This move increases market concentration and will likely apply significant competitive pressure on smaller diagnostic labs and genomics companies. These firms may now find it more difficult to compete with Zoetis’s scale, global distribution network, and newly integrated "prediction-to-treatment" service model.

However, the acquisition could also be a catalyst for broader industry innovation. With Zoetis's substantial R&D budget and market access, the GeneSeek platform is poised for accelerated development. This could lead to new, more advanced genomic tests and data analysis tools becoming available, ultimately raising the bar for the entire sector. Other major players in the animal health space may be spurred to seek their own strategic acquisitions or partnerships to keep pace.

The long-term impact on customers remains to be seen. While they stand to benefit from more powerful and integrated solutions, the reduction in the number of major genomics providers could eventually lead to concerns about pricing and choice. The industry will be watching closely to see how Zoetis leverages its strengthened market position in the years to come.

Navigating Regulatory Scrutiny and Integration

Before the deal can be finalized, it must pass a rigorous regulatory review process. The transaction’s extended closing timeline, projected for the first half of Neogen’s 2027 fiscal year, suggests that both companies anticipate a thorough examination by antitrust authorities in the U.S. and other jurisdictions. Regulators like the Federal Trade Commission will scrutinize the deal to ensure it does not unduly harm competition in the highly specialized market for animal genomic testing.

Assuming the deal receives regulatory clearance, the focus will shift to the complex task of integration. Neogen has committed to ensuring a smooth transition for customers and employees. For the staff of the genomics business, joining a company like Zoetis, which is deeply invested in animal health innovation, could present new opportunities for career growth and research. However, as with any major acquisition, some operational restructuring and alignment of corporate cultures will be inevitable.

Ultimately, this $160 million transaction represents a defining moment for both companies. For Neogen, it is a calculated retreat to a more defensible and profitable core. For Zoetis, it is an aggressive push into the future of animal health, betting big on the power of data and genomics to nurture the world by advancing the care of its animals.